Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive'
Target Price
The average target price of 476060.KQ is 12500 and suggests 1.63% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recomme